Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this early access program is to provide telaprevir to patients with a specific
type of hepatitis C viral infection (termed 'genotype 1') who are expected to benefit from
telaprevir-based therapy but who reside in countries in which telaprevir is not yet
commercially available and who are not eligible for enrollment into a clinical study of
telaprevir. The study also aims to collect information on the safety and adverse events with
telaprevir treatment in combination with peginterferon alfa and ribavirin, which is typically
used to treat patients with hepatitis C. In addition to hepatitis C viral infection, patients
in this study will also have a diagnosis of liver fibrosis and compensated liver disease.